BYOT Stock Overview
Byotrol plc develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Byotrol plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.026 |
| 52 Week Low | UK£0.0005 |
| Beta | -0.51 |
| 1 Month Change | -33.33% |
| 3 Month Change | -84.00% |
| 1 Year Change | -94.12% |
| 3 Year Change | -98.58% |
| 5 Year Change | -95.74% |
| Change since IPO | -99.66% |
Recent News & Updates
Recent updates
With EPS Growth And More, Byotrol (LON:BYOT) Is Interesting
Dec 08
If You Like EPS Growth Then Check Out Byotrol (LON:BYOT) Before It's Too Late
Apr 07Here's Why We Don't Think Byotrol's (LON:BYOT) Statutory Earnings Reflect Its Underlying Earnings Potential
Feb 18Is Byotrol plc's (LON:BYOT) Recent Performance Tethered To Its Attractive Financial Prospects?
Jan 28Here's Why We Think Byotrol (LON:BYOT) Is Well Worth Watching
Jan 07How Much is Byotrol's (LON:BYOT) CEO Getting Paid?
Dec 16Byotrol plc's (LON:BYOT) P/E Is On The Mark
Nov 25
Shareholder Returns
| BYOT | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | -20.0% | -3.0% | 1.2% |
| 1Y | -94.1% | -36.6% | 2.3% |
Return vs Industry: BYOT underperformed the UK Chemicals industry which returned -37.5% over the past year.
Return vs Market: BYOT underperformed the UK Market which returned 1.4% over the past year.
Price Volatility
| BYOT volatility | |
|---|---|
| BYOT Average Weekly Movement | 66.3% |
| Chemicals Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BYOT's share price has been volatile over the past 3 months.
Volatility Over Time: BYOT's weekly volatility has increased from 34% to 66% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 36 | David Traynor | byotrolplc.com |
Byotrol plc develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally. The company operates through Professional and Consumer segments. Its product portfolio includes Actizone, a antimicrobial technology which improves cleaning performance and long-lasting protection against bacteria; and Byotrol, a long-lasting antimicrobial protection for various applications including bathroom cleaners to multi-surface wipes.
Byotrol plc Fundamentals Summary
| BYOT fundamental statistics | |
|---|---|
| Market cap | UK£453.89k |
| Earnings (TTM) | -UK£1.85m |
| Revenue (TTM) | UK£4.38m |
0.1x
P/S Ratio-0.2x
P/E RatioIs BYOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BYOT income statement (TTM) | |
|---|---|
| Revenue | UK£4.38m |
| Cost of Revenue | UK£2.52m |
| Gross Profit | UK£1.86m |
| Other Expenses | UK£3.72m |
| Earnings | -UK£1.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 42.51% |
| Net Profit Margin | -42.33% |
| Debt/Equity Ratio | 19.7% |
How did BYOT perform over the long term?
See historical performance and comparison